Compounds as opioid receptor modulators

Details Compounds as opioid receptor modulators Compounds as opioid receptor modulators

2007-04-10

2007-04-10

Aulakh, Charanjit S. (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carboxylic acids and salts thereof

C546S314000, C562S443000, C562S448000, C560S038000, C564S182000

Reexamination Certificate

active

11079573

ABSTRACT:
This invention is directed towards novel compounds as opioid receptor modulators, antagonists, and agonists useful for the treatment of opioid modulated disorders such as pain and gastrointestinal disorders.

REFERENCES:
patent: 3023235 (1962-02-01), Leonard
patent: 3763218 (1973-10-01), Kaiser et al.
patent: 4563306 (1986-01-01), Sugano et al.
patent: 5863947 (1999-01-01), Baker et al.
patent: 2002/0161189 (2002-10-01), Lazarus et al.
patent: 0506468 (1992-09-01), None
patent: 2735776 (1996-12-01), None
patent: 5339240 (1993-12-01), None
patent: WO 96/06855 (1996-03-01), None
patent: WO 02/36116 (2002-05-01), None
D.S. Fries, “Analgesics”, inPrinciples of Medicinal Chemistry, 4th ed.; W.O. Foye, T.L. Lemke, and D.A. Williams, Eds.; Williams and Wilkins: Baltimore, Md., 1995; pp. 247-269.
J.V. Aldrich, “Analgesics”,Burger's Medicinal Chemistry and Drug Discovery, 5thEdition, vol. 3: Therapeutic Agents, John Wiley & Sons, Inc., 1996, pp. 321-441.
Pierre J.M. Riviere and Jean-Louis Junien, “Opioid receptors: Targets for new gastrointestinal drug development”, Drug Development 2000, pp. 203-238.
Brian J. Marsden, Thi M.-D. Nguyen and Peter W. Schiller, “Spontaneous degradation via diketopiperazine formation of peptides containing a tetrahydroisoquinoline-3-carboxylic acid residue in the 2-position of the peptide sequence”, Int. J. Pept. Protein Res. 1993, 41 (3), pp. 313-316.
Gianfranco Balboni et al., “Opioid pseudopeptides containing heteroaromatic or heteroaliphatic nuclei”,Peptides 2000, 21, pp. 1663-1671.
Mark P. Wentland et al., “3-Carboxamido Analogues of Morphine and Naltrexone: Synthesis and Opioid Receptor Binding Properties”,Biorganic&Medicinal Chemistry Letters2001, 11, pp. 1717-1721.
Mark P. Wentland et al., “8-Carboxamidocyclazocine Analogues: Redefining the Structure-Activity Relationships of 2,6-Methano-3-benzazocines”,Biorganic&Medicinal Chemistry Letters2001, 11, pp. 623-626.
Philip L. Gould, “Salt selection for basic drugs”, International Journal of Pharmaceutics, vol. 33, (1986) pp. 201-217.
Stephen M. Berge et al., “Pharmaceutical Salts”,Journal of Pharmacedutical Sciences, 1977 (Jan.), vol. 66, No. 1, pp. 1-19.
Tao Ye, et al., “Synthesis of Chiral N-Protected α-Amino-β-Diketones from α-Diazoketones Derived from Natural Amino Acids”,Tetrahedron1992, vol. 48, No. 37, pp. 8007-8022.
Kouichi Kikuchi et al., “Syntheses and Structure-Activity Relationships of 5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-quinoxaline Derivatives with Retinoic Acid Receptor α Agonistic Activity”,J. Med. Chem.2000, 43, pp. 409-419.
Gianfranco Balboni et al., “Evaluation of the Dmt-Tic Pharmacophore: Conversion of a Potent ō-Opioid Receptor Antagonist into a Potent ō Agonist and Ligands with Mixed Properties”, J. Med. Chem. 2002, 45, 713-720.
Marnix A. Hoitink et al., “Degradation of Azaglycinamido Residues in Model Tripeptides Derived from Goserelin”, Journal of Pharmaceutical Sciences, vol. 89, No. 1, Jan. 200, pp. 108-114.
Severo Salvadori et al., “Evolution of the Dmt-Tic Pharmacophonre: N-Terminal Methylated Derivatives with Extraordinary ō Opioid Antagonist Activity”, J. Med. Chem. 1997, 40, 3100-3108.
H. Maeda et al., “Synthesis and Central Nervous System Actions of Thyrotropin-Releasing Hormone Analogs Containing a 1-Oxo-12,3,4-tetrahydroisoquinoline Moiety1”, Chem. Pharm. Bull. 36(1) 1988, pp. 190-201.
H. Obase et al., “New Antihypertensive Agents II. Studies on New Anaolog of 4-Piperidylbenzimidazolinones” Chemical and Pharmaceutical Bulletin, Pharmaceutical Society of Japan, Tokyo, Up. vol. 30, No. 2, 1982, pp. 474-483 XP000974108.
Tripp et al., “Synthesis of methylene-and carbonyl-bridged analogs of iodothyronines and iodothyroacetic acids”, Journal of Medicinal Chemistry, American Chemical Society, Washington, U.S. vol. 16, No. 1, 1973, pp. 60-64, XP002113321.
P.J. Krenitsky, “Preparation of the 14-membered 1, 1-cyloisodityrosone subunit of RP 66453” Tetrahedron Letters, Elsevier Science Publishers, Amsterdam, NL, vol. 43, No. 3, Jan. 14, 2002, pp. 407-410, XP004329390.
F. Leonard et al., “Unnatural amino acids. II. Congeners of DI-3-carboxy-4-methoxyphenylalanine” J. Med. Chem. vol. 10, 1967, pp. 478-481, XP00258212.
Krenitsky P J et al, “Preparation of the 14-membered 1,1-cyloisodityrosine subunit of RP 66453” Tetrahedron Letters, Elsevier Science Publishers, Amsterdam, NL, vol. 43, No. 3, p. 408.
Leonard, F. et al., Unnatural amino acids. II. “Congeeners of DL-3-Carboxy-4-methoxyphenylalanine”, J. Med. Chem. vol. 10, p. 408.
Maeda, H. etl al, “Synthesis and Central Nervous system actions of thyrotropin-releasing hormone analogs containing a 1-oxo-1,2,3, 4-tetrahydroisoquinolinc moiety”, Chem. Pharm. Bull. vol. 36, No. 1, p. 191.
PCT International Search Report PCT/US03/11872 dated Nov. 6, 2003.

Affiliated with

Also associated with

Rating

Compounds as opioid receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds as opioid receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds as opioid receptor modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3747014